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Abstract
PrP
C, a host protein which in prion-infected animals is converted to PrP
Sc, is linked to the cell membrane by a GPI anchor.
Mice expressing PrP
C without GPI anchor (tgGPI
- mice), are susceptible to prion infection but accumulate anchorless PrP
Sc
extra-, rather than intracellularly. We investigated whether tgGPI
2 mice could faithfully propagate prion strains despite the
deviant structure and location of anchorless PrP
Sc. We found that RML and ME7, but not 22L prions propagated in tgGPI
2
brain developed novel cell tropisms, as determined by the Cell Panel Assay (CPA). Surprisingly, the levels of proteinase K-
resistant PrP
Sc (PrP
res) in RML- or ME7-infected tgGPI
2 brain were 25–50 times higher than in wild-type brain. When returned
to wild-type brain, ME7 prions recovered their original properties, however RML prions had given rise to a novel prion strain,
designated SFL, which remained unchanged even after three passages in wild-type mice. Because both RML PrP
Sc and SFL
PrP
Sc are stably propagated in wild-type mice we propose that the two conformations are separated by a high activation
energy barrier which is abrogated in tgGPI
2 mice.
Citation: Mahal SP, Jablonski J, Suponitsky-Kroyter I, Oelschlegel AM, Herva ME, et al. (2012) Propagation of RML Prions in Mice Expressing PrP Devoid of GPI
Anchor Leads to Formation of a Novel, Stable Prion Strain. PLoS Pathog 8(6): e1002746. doi:10.1371/journal.ppat.1002746
Editor: Surachai Supattapone, Dartmouth Medical School, USA, United States of America
Received February 13, 2012; Accepted April 27, 2012; Published June 7, 2012
Copyright:  2012 Mahal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Institutes of Health 1RO1NSO59543, 1RO1NSO67214 and by a generous donation from the Alafi
Family Foundation to C.W. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: charlesw@scripps.edu
¤a Current address: Opko Pharmaceuticals, Jupiter, Florida, United States of America
¤b Current address: The Center for Brain Repair, Forvie Site, Cambridge, England
Introduction
Prions, the causative agents of transmissible spongiform
encephalopathies, contain as their main component PrP
Sc,a
multimeric conformer of the ubiquitous host protein PrP
C. PrP
C
can carry one or two N-linked glycans, whose structure is highly
variable [1–3], or remain unglycosylated; moreover the glycosyl-
ation state varies in different tissues and cell lines, and even in
different brain regions [4–6]. Most PrP
C is attached to the outer
surface of the plasma membrane by a glycosylphosphatidylinositol
(GPI) anchor [7], but transmembrane forms have been identified
[8,9]. In prion-infected cells PrP
C is converted to PrP
Sc at the
membrane [10] and within the endosomal-lysosomal compart-
ment [11], and accumulates mainly in intracellular compartments
[12,13]. While PrP
C is readily cleaved off the cell surface by
PIPLC [7], PrP
res is not, even though it retains its GPI anchor
[14]. PrP
Sc presents as a partially proteinase K (PK)-resistant form,
designated rPrP
Sc or PrP
res, or as a PK-sensitive entity, sPrP
Sc or
PrP
sen [15–17].
Mouse prions occur in the form of a wide variety of strains,
which have the same PrP sequence but differ in their incubation
time in various mouse lines and in the pattern of lesions they cause
in brain [18]. It is believed that strain-ness is encoded by the
conformation of PrP
Sc and in many instances there are differences
in the physicochemical properties of the cognate PrP
res [19–24].
Interestingly, different prion strains populate distinct regions of the
brain [25–27] and are selective in regard to the cultured cell lines
they can chronically infect [28–33]. This raises the unanswered
question as to which cellular property underlies prion strain
tropism.
The seeding or nucleation model for prion propagation [34–36]
predicates that PrP
C monomers add to PrP
Sc and in doing so
assume the conformation of its subunits, thus allowing faithful
propagation of strains. A prerequisite for chronic infection is that
PrP
C monomers with a conformation allowing efficient accretion
be present at a concentration sufficient to allow synthesis of PrP
Sc
at a rate higher than that of its depletion [37–39]. PrP
C is
conformationally very flexible [40–42] but certain conformations
may be more frequent in some cell types but less so or absent in
others, which could account for the tropism of prion strains. This
proposal begs the question as to why certain conformations would
be favored in some cells but not in others. One possibility is that
PrP
C conformation is modulated by the association of PrP
C with a
cell-specific component, RNA and phospholipids being two
possibilities among several [43,44]. PrP has a strong binding
affinity for polyanions, in particular RNA and homoribopolynu-
cleotides [45,46]. Binding of RNA causes conformational changes
of PrP [47,48] and in vitro conversion of purified PrP
C or
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Sc by Protein Misfolding Cyclic
Amplification (PMCA) requires the presence of a polyanion and/
or phospholipid [44,49–51]. Another possibility is that the highly
variable glycosylation of PrP
C observed in different cells and
tissues [52] might affect its susceptibility to conversion to PrP
Sc,
because of an effect on its conformation [53] or its interactions
with putative auxiliary host proteins such as the conjectured
protein X [54]. Distinct PrP
C glycoforms promote PMCA-
mediated prion formation in a species-specific manner [55].
There have been many attempts to explore the role of glycans in
the fidelity of strain propagation, in particular by generating
amino acid replacements at the glycosylation sites [53,56–58].
However, in these experiments failure to propagate prions or to
propagate them faithfully could be due to sequence changes,
which are known to affect efficiency of propagation and cause
strain shifts [59], rather than the lack of glycans. We were
therefore interested in investigating the effect of post-translational
modifications of PrP
C on the fidelity of strain propagation in the
absence of an amino acid sequence change.
Some years ago Chesebro et al. generated transgenic mice
lacking the PrP GPI signal sequence on a PrP null background
(tgGPI
2 mice) [60]. In mice hemizygous for the transgenes, PrP
devoid of the GPI anchor (GPI
2-PrP) was expressed at about one
quarter the level of PrP in wild-type controls, was largely
unglycosylated and absent from the plasma membrane. Nonethe-
less, these mice, inoculated with RML or 22L prions accumulated
high levels of infectivity and PK-resistant PrP in the form of
extracellular amyloid plaques in their brains, but exhibited no
striking clinical signs up to 600 and 400 days post infection (dpi),
respectively. GPI
2-PrP
C to GPI
2-PrP
Sc conversion is believed to
occur extracellularly [11,60–62]. Mice homozygous for the
transgenes expressing GPI
2-PrP at a twofold higher level than
their hemizygous counterparts developed neurological signs from
300 to 480 dpi [63]. Cultured cells expressing GPI
2-PrP secreted
the bulk of the anchorless PrP into the medium, none was found at
the cell surface but some was associated with membrane fractions
[64]. Cells expressing epitope-tagged GPI
2-PrP exposed to 22L
prions did not become chronically infected, however during the
acute infection phase, tagged PrP
res was transiently formed
[61,65].
To determine whether prions formed from PrP
C that had the
same sequence but different post-translational modifications would
retain their strain characteristics, we inoculated tgGPI
2 mice with
various prion strains or isolates and determined the cell tropism of
the resulting isolates by the Cell Panel Assay (CPA) [33]. We found
that the CPA properties of 22L prions remained unchanged,
whereas those of RML, 139A, 79A and ME7 prions became
distinctly different when propagated in tgGPI
2 mice. RML, 139A
and 79A prions are derived from drowsy goat scrapie and are
related [66,67] while ME7 and 22L are distinct and unrelated
strains derived from sheep scrapie [68]. Because the changes in
properties could have been due to the absence of the GPI anchor
and/or to diminished glycosylation, RML and ME7 prions
propagated in GPI
2 mice were transferred to wild-type mice
and their properties were again assessed. As judged by the CPA,
ME7 prions recovered their original properties after one passage,
showing that their adaptation to the GPI
2 environment was
readily reversible. RML-derived prions, however, did not recover
their original cell tropism, even after three cycles of propagation in
wild-type mice, and therefore constituted a novel, stable strain,
which we designated ‘‘SFL’’ (‘‘Scripps Florida Laboratory’’).
Because both RML and SFL prions were stably propagated in
wild-type mice, we propose that the two conformations are
separated by a high activation energy barrier which is abrogated in
tgGPI
2 mice, either because of the different structure or reduced
expression level of the hypoglycosylated GPI-less PrP
C, or because
of a different replication mode in the extracellular space.
Results
Inoculation of tgGPI
2 mice with various prion strains
TgGPI
2 mice express a PrP construct in which a nonsense
codon replaces that for serine233, the residue to which the GPI
moiety is added in wild-type PrP; thus, the polypeptide chains are
identical in the transgenic and wild-type mice [60].
TgGPI
2 mice [60] (GPI
2 for short) and C57BL/6 wild-type
mice (C57 for short) were inoculated with the mouse-adapted
scrapie prion strains 22L, RML, 79A, 139A and ME7 to give
GPI
2[22L], GPI
2[RML], GPI
2[79A], GPI
2[139A] and
GPI
2[ME7] prions (Table S1). GPI
2[ME7] and GPI
2[RML]
brain homogenate was injected into GPI
2 mice for a second round
of transmission, to give GPI
2/GPI
2[ME7] and GPI
2/
GPI
2[RML] mice. Disease signs in GPI
2 mice occurred later
than in C57 mice; for example, RML caused terminal disease at
.300 days after inoculation (dpi) in GPI
2, and at about 142 dpi in
C57 mice, similar to the values reported previously [63].
GPI
2[RML] elicited disease in GPI
2 mice after 263647 dpi,
suggesting adaptation of the RML prions to the novel environ-
ment.
Comparative quantitation of PrP
res by Western blotting
and sandwich ELISA
We first analyzed the prion-infected brain samples for their
content of PrP
res. Western blot analysis of C57[RML] and
C57[ME7] brain homogenates showed three PrP-specific bands,
attributed to di-, mono- and unglycosylated species, whose
mobility increased after truncation by PK digestion (Figure 1A,
lanes 1,2 and 9,10 respectively). The same amount or threefold
higher of GPI
2[ME7] sample gave no detectable PrP signal (lanes
11–14), while GPI
2/GPI
2[ME7] (lane 17) and GPI
2[RML] (lane
5) samples gave rise to a ladder of bands with mobilities
corresponding to about 28 to .250 kDa. Treatment with PK
Author Summary
The agent causing transmissible spongiform encephalop-
athies, the prion, consists mainly if not entirely of PrP
Sc,a n
aggregated conformational variant of PrP
C. PrP
C is a host-
specified glycoprotein which is attached to the outer
surface of the plasma membrane by a glycosylpho-
sphatidylinositol (GPI) anchor. PrP
Sc is thought to propa-
gate by seeded conversion, in which PrP
C accretes to an
aggregate of PrP
Sc and thereby assumes its conformation.
Prions occur as distinct strains, which have the same PrP
sequence but different PrP
Sc conformations. Many strains
are very stable but some can ‘‘mutate’’, especially after
transient propagation in another animal species. Here
‘‘mutation’’ is attributed to a conformational change of the
underlying PrP
Sc protein rather than a change in the
nucleotide sequence of a gene. In transgenic mice that
express anchorless PrP, conversion to PrP
Sc occurs extra-
cellularly rather than in a cell-associated compartment.
Surprisingly, RML, a very stable prion strain, when
propagated in tgGPI
2 mice and then returned to wild-
type mice, was recovered as a novel strain, designated SFL,
which was stable over many transmissions. Thus, faithful
strain propagation was abrogated either as a consequence
of the modified PrP or because of a different replication
mode in the extracellular compartment of tgGPI
2 brain.
RML Converted to a Novel, Stable Prion Strain
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corresponding to unglycosylated and the minor one to mono-
glycosylated GPI
2PrP, as shown by the fact that PNGase digestion
abrogates the slower-moving band (Figure 1B, lanes 2 and 12).
The aggregated forms of GPI
2-PrP are likely derived from the
abundant amyloid plaques described earlier [60]. Although
GPI
2[ME7] brain homogenate from mice culled at 300 dpi
showed barely a trace, if any at all, of PrP
res on western blots
(Figure 1A, lanes 12, 14) it nonetheless caused clinical disease by
about 170 and 450 dpi when inoculated into wild-type and GPI
2
mice, respectively (Table S1, #20, 21), raising the suspicion that
quantitation by western blot was erroneous. Nishina and
Supattapone have reported that PrP
C deprived of a GPI anchor
by PIPLC-treatment was retained by the PVDF membranes used
for western blotting at less than about 5% the efficiency of its GPI-
linked counterpart [69]. We therefore compared the levels of
PrP
res in PK-treated samples from GPI
2 and C57 mice by western
blotting and by sandwich ELISA, in which PK-treated, denatured
samples were bound to wells coated with anti-PrP antibody D18
and visualized with biotinylated antibody D13. Astonishingly,
sandwich ELISA revealed levels of PrP
res in GPI
2[RML] and
GPI
2/GPI
2[ME7] brain 50- and 25-fold higher, respectively,
than those in C57[RML] brain (Figure 1C) rather than 30% and
.50% lower, as indicated by western blotting (Figure 1A).
Figure 1D shows that quantitation of PrP
res by western blotting
and sandwich ELISA are consistent for wild-type brain but highly
discordant for GPI
2 brain. Moreover, sandwich ELISA showed
that the GPI
2[ME7] samples, which were negative by western
blotting, in fact contained PrP
res at about 12% the level in
C57[ME7] brains. Brains from GPI
2 mice infected with 22L, 79A
and 139A were not examined by western blotting or sandwich
ELISA.
In summary, using the sandwich assay rather than western
blotting for the quantitation of PrP
res, it became evident that RML
and ME7 prions propagating in GPI
2 mice gave rise to unusually
high levels of PrP
res, likely due to greater stability of extracellular
as compared to intracellular PrP
res.
Characterization of GPI
2[RML] and C57[RML] prions by
the CPA
Homogenates of prion-infected brains from GPI
2 and C57
mice were analyzed by the CPA. In this assay, the cell lines CAD,
PK1, LD9 and R332H11 are infected with serial dilutions of a prion
preparation and the proportion of infected cells is plotted against
the logarithm of the dilution. The Response Index (RI) is defined
as the dilution of the prion preparation at which an arbitrary
proportion of cells (in this paper usually 3%) becomes PrP
res
positive. The ratio of RI’s for a prion preparation on a set of cell
lines is a characteristic strain property [2]. Additional valuable
strain discrimination is provided by the glycosylation inhibitors
swainsonine (swa), kifunensine (kifu) and castanospermine (csp),
which inhibit chronic infection of PK1 cells by various strains to
different extents [70]. Swa [70–72] and kifu [71] are potent and
selective inhibitors of class II and class I a-mannosidases,
respectively, and lead to replacement of complex N-glycans by
high-mannose glycans. Csp [72], by inhibiting glucosidases, causes
replacement of complex glycans mainly by glucose-containing,
high-mannose oligosaccharides.
As shown by the CPA in Figure 2A, RML prions from C57
brain were swa sensitive on PK1 cells and R33
2H11 incompetent,
i.e. unable to infect R33
2H11 cells efficiently, while RML-derived
prions from GPI
2 brain were swa resistant and R33
2H11
competent; moreover, the RICAD/RIPK1 ratio was lower for the
C57-derived than for the GPI
2-derived samples. The bar diagram
(Figure 2B) shows log[RICAD/RIPK1] (blue) and log[RIPK1/
RIPK1+swa] (red) values plotted for 22L, RML, 79A, and 139A,
propagated in C57 or GPI
2 brain. The quantified data clearly
show that C57[RML] and GPI
2[RML] give vastly different
patterns, as do their 79A and 139A counterparts. The statistical
significance of the ‘‘log[ratio]’’ differences between two strains is
given in the matrix of Figure 2C. For example, the difference
between C57[RML] and GPI
2[RML] is highly significant for
both ratios, whereas there is no significant difference between
C57[22L] and GPI
2[22L] by the criteria used here. Interestingly,
the differences between C57[RML] and C57[139A] are significant
for both ratios, but not those between C57[RML] and C57[79A],
contradicting the common assumption that RML and 139A are
the same strains [67] and confirming the cognate conclusions of
Browning et al. [73] and Oelschlegel et al. (personal communi-
cation).
From the RI values shown in the Figures and the PrP
res content
relative to RML (Figure 1D) the relative specific infectivities (RI/
PrP
res) of RML and ME7 prions (second passage) derived from
GPI
2 mice were calculated and found to be 6- and 25-fold lower,
respectively, than those from C57 mice (Table 1), suggesting that
PrP
res accumulating extracellularly was either inherently less
infectious or lost infectivity over time.
Transfer of GPI
2 [RML] prions to C57BL/6 mice
Because PrP
C and PrP
res in GPI
2 mice lack the GPI anchor and
are also largely unglycosylated (Figure 1B) [1], the question arose
whether the differences in the CPA characteristics of GPI
2-
derived and wild-type prions were due to these structural features
(which we considered unlikely because GPI-linked PrP
res arises
immediately after infecting the cells for the CPA) or to a
conformational change of the PrP
res. We therefore inoculated
brain homogenate from GPI
2[RML] mice into C57BL/6 mice to
generate C57/GPI
2[RML] prions, whose PrP
res then carried a
GPI anchor and was normally glycosylated (Figure 1B, lanes 5).
The resulting brain homogenate was serially transmitted twice
more to C57BL/6 mice, to yield C57/C57/GPI
2[RML]
(Figure 1B, lanes 7, 8) and C57/C57/C57/GPI
2[RML] prions
(Figure 1B, lanes 9, 10; Figure 1A, lanes 3, 4).
C57BL/6 mice inoculated with prions from GPI
2[RML] brain
exhibited pronounced clinical signs of RML scrapie disease after
15069 days, similar to those of mice inoculated with the original
C57[RML] (Table S1, #4a,b; #1). However, as shown in
Figure 3A, C57/GPI
2[RML] prions neither retained the drug
susceptibility pattern of GPI
2[RML], nor did they regain the
pattern characteristic for the original C57[RML] prions, even
after two additional transfers through C57 mice. From the bar
diagram (Figure 3B) it can be seen that the log[RIPK1/RIPK1+kifu]
(blue) and log[RIPK1/RIPK1+swa] (red) values for C57/
GPI
2[RML] and C57/C57/C57/GPI
2[RML] prions, 0.6, 0.7,
and 0.7, 0.8, respectively, were indistinguishable, but far lower
than those for C57[RML] prions, .2.8 and 1.4, respectively. The
statistical evaluation shown in the matrix of Figure 3C confirms
the significance of these conclusions.
In a further experiment (Figure 3D), the susceptibility of prion
replication in PK1 cells to inhibition by csp and, again, kifu was
tested. The bar diagram (Figure 3E, blue bars) shows that kifu, as
before, inhibited infection of PK1 cells by RML by more than 3
logs but had little effect on infection by C57/GPI
2[RML] or
C57/C57/GPI
2[RML] prions, and Figure 3F documents the
statistical significance of the conclusions. In addition, we cloned
RML prions in PK1 cells, propagated them in mouse brain and
determined that none of twelve RML subclones exhibited kifu
resistance, excluding the possibility that SFL was a significant
RML Converted to a Novel, Stable Prion Strain
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inhibited RML infection of PK1 cells by about 2 logs, but that of
GPI
2-derived prions passaged once or twice in C57 mice by only
about 1 log (Figure 3E, green bars). Thus, as judged by the CPA
and by inhibitor susceptibility, RML prions passaged through
GPI
2 brain acquired novel characteristics and these were retained
even after three serial passages through C57BL/6 brain.
The conformational stability assay [26] showed no difference
between the PrP
res associated with wild-type RML, C57/
GPI
2[RML] and C57/C57/GPI
2[RML], however GPI
2[RML]
PrP
res seemed slightly more stable; whether this reflects a
conformational difference or a difference due to the absence
of GPI anchor and paucity of N-glycans remains unknown
(Figure S2).
Figure 1. PrP
res in RML- and ME7-infected wild-type and tgGPI
- mouse brains, quantified by Western blot and sandwich ELISA. (A)
Western blot of RML
2 and ME7-infected brain homogenates before and after PK treatment. ‘‘mg’’, total protein loaded. ‘r’, 2.5 ng recombinant murine
PrP (recPrP). GPI
2[RML] (lanes 5, 7) and GPI
2/GPI
2[ME7] (lane 17) brain homogenates gave rise to ladders reflecting multimers with molecular
weights extending to .250 kDa, which were reduced to monomers by PK digestion, while GPI
2[ME7] homogenate gave no detectable signals. (B)
Western blot of PK-digested brain homogenates treated or not with PNGase. Lanes 3, 5, 7, 9 show, from top to bottom, diglycosylated,
monoglycosylated and unglycosylated, truncated PrP; PNGase-treated samples (lanes 4, 6, 8, 10) show a single band corresponding to
unglycosylated, truncated PrP. Samples from tgGPI
2 mice (lanes 1, 11) show two bands, corresponding to truncated, monoglycosylated (top) and
unglycosylated PrP, and, after PNGase treatment, a single band corresponding to truncated, deglycosylated PrP (lanes 2, 12). Because anchorless PrP
is retained inefficiently by PVDF membranes [69], 24 times more total protein was loaded for GPI
2 than for C57 samples, to give about the same
signal strength. (C) Sandwich ELISA of PK-treated samples. Absorbance of quadruplicate samples is plotted against log[input protein]. Samples a to g
are identified in panel D; h, uninfected C57 brain homogenate. The abundance of a sample relative to that of RML can be read off by comparing the
amounts of protein required to give the same absorbance. For example, an absorbance of 0.1 is given by 0.01 mg GPI
2[RML] and 0.5 mg C57[RML]
brain homogenate (total protein prior to PK treatment), therefore the abundance of GPI
2[RML] is about 50 times higher than that of C57[RML] PrP
res.
In Figure S2 absorbance of the same samples is plotted against input protein on a linear scale, to show that the response is almost linear up to a
protein input of 1.5 mg/well. (D) The PrP
res signals (‘‘pix’’) from the western blots of Figure 1A were quantified relative to C57[RML] and the log of the
ratio was plotted (red bars). For the sandwich ELISA, the plot shows the log of the absorbance (A) relative to that of C57[RML] (blue bars).
doi:10.1371/journal.ppat.1002746.g001
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2 mice. Homogenates of GPI
2 or C57 brains
infected with the strains indicated were subjected to the CPA. (A) The patterns elicited by 22L from both sources were very similar, however RML, 79A
and 139A prions from wild-type brain were swa sensitive on PK1 cells and R33
2H11 incompetent, while those from tgGPI
2 brain were swa resistant
RML Converted to a Novel, Stable Prion Strain
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2[ME7] and C57[ME7] prions by
the CPA
Typical scrapie signs were not observed in ME7-inoculated
GPI
2 mice by 300–305 days, at which time mice showing mild
clinical signs were euthanized and homogenates of their brains
were subjected to the CPA. The level of infectivity of GPI
2[ME7]
brain homogenates as measured on CAD and PK1 cells was very
low (RI,10
3), however LD9 cells showed a higher response
(RI=1.1610
4), albeit at a level about 25 times lower than that
found for C57[ME7] brains 2.8610
5 (Figure 4). The GPI
2[ME7]
brain homogenates were infectious to wild-type mice, leading to
disease at 17060 dpi (Table S1, #20), as compared to 13864
days for ‘‘normal’’ C57[ME7] (Table S1, #18b), and yielded
prions indistinguishable from the original ME7, as judged by the
CPA. A second transmission of GPI
2[ME7] prions to GPI
2 mice
resulted in disease at 447664 dpi (Table S1, #21) and,
interestingly, to high levels of PrP
res, as determined by sandwich
ELISA (Figure 1C, 1D), and infectivity, as measured on CAD cells
(RI=1.5610
5; Figure 4A). GPI
2/GPI
2[ME7] prions differed
from C57[ME7] prions by their log[RILD9/RICAD] value, -0.03
versus 0.7; whether or not they revert to the original ME7 after
being returned to C57 is still under investigation (Table S1, 22.)
(Figure 4B, C). In summary, repeated propagation of ME7 prions
through GPI
2 brain resulted in a distinct alteration of their
properties, reflecting progressive adaptation to the modified
environment. However, prions returned from GPI
2[ME7] mice
to C57 mice resulted in reversion to prions indistinguishable from
the original C57[ME7] prions.
Discussion
Prion populations are considered to be ‘‘quasi-species’’, i.e. to
consist of a major component and a multiplicity of variants present
at low levels, of which one may be selected as the major
component if the population is exposed to a different environment
[39,74,75].
We have reported previously that when 22L prions were
transferred from brain to PK1 or R33 cells, their properties, as
measured by the CPA, changed gradually in the course of many
doublings, suggesting that a 22L variant present at low levels in the
brain-derived population was being selected in the cellular
environment. Conversely, when the cell-adapted 22L variants
were again propagated in brain, the resulting population gradually
re-acquired the properties of the original brain-derived 22L. When
22L prions were cloned by endpoint dilution into PK1 cells they
were initially swa sensitive and incapable of developing swa
resistance (‘‘swa incompetent’’), but as the populations were
further propagated they became swa competent while remaining
swa sensitive, suggesting that during propagation swa-resistant
prions arose at a low level by ‘‘mutation’’ and could be selected
when the population was challenged with swa [74–76].
In all these cases the changes were reversed when the prions
were propagated in the original environment; assuming that
properties of prions are encoded by the precise conformation of
the cognate PrP
Sc, we concluded that the conformational states
underlying adaptation to the cellular environment are separated
by low activation energy barriers which allowed reversible
conformational switches leading to ‘‘strain variants’’ or ‘‘sub-
and R33
2H1 competent. The RI600 (Response Index for 600 spots) on CAD, PK1, PK1+swa and R33
2H11 cells is given within the graphs (left upper corner)
and the logarithm 6 SD of the ratios RICAD/RIPK1 (blue) and RIPK1/RIPK1+swa (red) is plotted in the bar graph (B). The matrix (C) gives the p values for the
pairwise comparison of two strains on the basis of their log[RICAD/RIPK1] (blue) and log[RIPK1/RIPK1+swa] (red) values. The framed ‘‘ns’’ indicates p
values.0.1 for both log[ratios]. For example, C57[RML] and GPI
2[RML] prions are significantly different (p=0.0097 for log[RICAD/RIPK1] and p=0.0001
for log[RIPK1/RIPK1+swa]), as are C57[79A] and GPI
2[79A] prions, whereas C57[22L] and GPI
2[22L] prions do not show a significant difference (framed
‘‘ns’’; p.0.1) for both logRI ratios. By the same token C57[79A] and C57[RML], and GPI
2[139A] and GPI
2[RML] prions are not distinguishable, while
C57[139A] and C57[RML] prions differ.
doi:10.1371/journal.ppat.1002746.g002
Table 1. Relative specific infectivity of various prion species.
Relative specific infectivity
Prion species Relative RI ± SD* Relative PrPres ± SD
+ RI/PrP
res ± SD
#
Comparison to wild-type prions
by the t test (p values)
A C57[RML] 1.060.4 1.060.06 1.060.4 -
GPI
2[RML] 7.2663.03 45.766.83 0.1660.07 0.006
C57/C57/C57/GPI
2[RML] 1.0560.46 1.6260.32 0.6560.31 ns
B C57[ME7] 1.060.33 1.060.06 1.060.34 -
GPI
2[ME7] 0.0460.014 0.1360.012 0.2860.11 0.0069
GPI
2/GPI
2[ME7] 0.5160.23 13.860.92 0.0460.02 0.0013
C57/GPI
2[ME7] 0.5860.22 0.6460.112 0.9160.38 ns
ns, not significant. All determinations were in quadruplicate.
*RI’s were determined on PK1 cells (A) or LD9 cells (B) by the SSCA and expressed relative to the values found for C57[RML] (A) or C57[ME7] (B).
+PrP
res was determined by Sandwich ELISA as shown in Figure 1C and expressed relative to the values found for C57[RML] (A) or C57[ME7] (B).
#Relative specific infectivity is the ratio RI/PrP
res relative to that of C57[RML] (A) or C57[ME7] (B).
The specific infectivity of GPI
2[RML] is 6 times lower than that of C57[RML] prions, and that of GPI
2/GPI
2[ME7] is 25 times lower than that of C57[ME7] prions,
underlining the changed properties of prions adapted to GPI
2 brain. After being returned to and propagated in wild-type brain, C57/C57/C57/GPI
2[RML] prions (which
show a novel, stable CPA response and constitute a novel strain, designated SFL) do not fully regain the specific infectivity of RML, however the difference is not
statistically significant. ME7 prions fully regain the original specific infectivity on being returned from GPI
2 to wild-type mice.
doi:10.1371/journal.ppat.1002746.t001
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2 mice and returned to wild-type mice emerge as a novel, stable strain. Analysis of authentic
RML prions propagated in C57BL/6 brain (C57[RML]), and of RML prions first propagated in GPI
2 brain (GPI
2[RML]) and then once (C57/GPI
2[RML]),
twice (C57/C57/GPI
2[RML]) or three times (C57/C57/C57/GPI
2[RML]) in C57BL/6 brain. (A) shows the SSCA performed on PK1 cells in the presence or
absence of kifunensine (kifu; 5 mg/ml) or swainsonine (swa; 2 mg/ml) for the samples indicated; C57[22L] was added as control. RI’s were determined
at 600 spots (RI600). Kifu strongly inhibited the propagation of C57[RML], but not of C57/GPI
2[RML] and C57/C57/C57/GPI
2[RML] prions on PK1 cells.
(B) The bar graph shows the log[RIPK1/RIPK1+kifu] and log[RIPK1/RIPK1+swa] values for the samples listed in (A). The pairwise comparison in panel (C)
shows that C57/GPI
2[RML] and C57/C57/C57/GPI
2[RML] prions do not differ significantly, but are vastly different from C57[RML] and GPI
2[RML]
prions. The framed ‘‘ns’’ indicates high p values (.0.1) for both log[ratios], indicating no significant difference between the samples. (D) Effect of
castanospermine (csp; 50 mg/ml) or kifu (5 mg/ml) on propagation of the samples indicated on PK1 cells. As in (A), kifu strongly inhibits the
propagation of C57[RML], but not C57/GPI
2[RML] and C57/C57/GPI
2[RML] prions. The same is true for csp, however to a lesser extent. (E) The bar
graph depicts the log[RIPK1/RIPK1+kifu] (blue) and log[RIPK1/RIPK1+csp] (green) values. The RIPK1/RIPK1+kifu ratio was .500-fold lower for C57/GPI
2[RML]
RML Converted to a Novel, Stable Prion Strain
PLoS Pathogens | www.plospathogens.org 7 June 2012 | Volume 8 | Issue 6 | e1002746strains’’ [75]. In contrast to these earlier results with 22L prions,
we now report that when RML prions from wild-type brain were
propagated in brain producing anchorless PrP, a GPI
2-PrP
Sc
conformer adapted to that environment evolved, and when this
was transferred to wild-type mice, a novel conformation of wild-
type PrP
Sc, which we designated SFL, distinct from that of the
original RML, was stably maintained. Because SFL does not
revert to RML, it must be either better adapted to propagation in
wild-type brain, prevented from reverting by a high activation
energy barrier or both (Figure 5). Of note, methods commonly
used to distinguish strains, such as incubation period, western
blotting or conformational stability assays could not differentiate
between RML and SFL, whereas this was readily achieved with
the Extended Cell Panel Assay (ECPA) [77]. ME7 also acquired
distinct properties when propagated in tgGPI
2 brain, however it
reverted to what appears to be its original form when passaged
through wild-type brain. Strain switching has been observed
previously in transfer between animal species, when 139A prions
were transferred from mouse to hamster and back to mouse [78];
in that case, a different amino acid sequence in the intermediate
host may have led to the adoption of a more favorable
conformation, which was preserved when the prions were returned
to the original host. Mutated PrP
Sc could be formed if accretion of
GPI
2-PrP
C to wild-type seed entailed adoption of a conformation
slightly different from that of the seed, or if wild-type PrP
Sc
contained a variety of mutant seeds –possibly at a low level– to one
or some of which the resident GPI
2PrP
C preferentially accreted,
adopting its conformation [76].
Considering the large variety of ‘‘classical’’ murine prion strains
[79], the plethora of strains generated by Prusiner and his
colleagues [80,81] and the many variants we have observed, all
encoded by a single murine PrP sequence, the number of stable
conformational states must be vast. The structural elucidation of
PrP
Sc and its variants continues to be the Holy Grail of the prion
field.
Materials and Methods
Ethics statement
When working with mice all efforts were made to minimize
suffering. This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institute of Health. The
protocol was approved by the Institutional Animal Care and Use
Committee (IACUC). Scripps Florida has an Animal Welfare
Assurance on file with the Office of Laboratory Animal Welfare
(OLAW), National Institute of Health (assurance number
#A4460-01). Scripps Florida’s registration under USDA regula-
tions is certificate 93-R0015. The Association for Assessment and
Accreditation of Laboratory Animal Care International (AAA-
LAC) awarded Scripps Florida full accreditation.
Mouse inoculations
C57BL/6 mice were from Charles River Laboratories (Wil-
mington, MA). Breeding pairs of tgGPI
2 mice [60] were obtained
from the Oldstone laboratory. Mice were anesthetized by
isoflurane and 30-ml samples of 1% brain homogenates were
inoculated in the prefrontal cortex. When pronounced clinical
signs became evident, or earlier, the mice were asphyxiated with
CO2 and subjected to cervical dislocation.
Prion preparations
The 22L strain, cloned by two successive end-point dilutions, as
well as strains 79A and 139A were obtained from the TSE
Resource Centre, Compton, Newbury, UK (I. McConnell, R.M.
Barron). The RML strain, from the MRC Prion Unit, University
College, London, was propagated initially in CD1 mice and
subsequently in C57BL/6 mice.
Brains were harvested from mice exhibiting neurological signs
of prion diseases in C57BL/6. In some cases where inoculated,
anchorless mice showed only mild clinical signs, brains were taken
at 300 days post inoculation. For stock homogenates, frozen brains
were pooled and homogenized for 10 sec in PBS (9 ml per g) using
a hand-held Ultramax T18 basic homogenizer (IKA Works Inc.,
Bloomington, NC) at 20000–25000 rpm. Single frozen brains
were homogenized in PBS using a ribolyser (FastPrep FP120, Bio
101, Thermo Electron Corp.,Thermo Fischer Scientific, MA) with
ZrO 0.8–1 mm beads (cat. No. 7305-000010, Glen Mills Inc.
Clifton, NJ), at maximum speed 6.5 for 15 seconds in Fast Prep
tubes (MP Biomedicals).
Cell culture
The cell lines PK1 and R332H11 are derived from N2a
neuroblastoma cells, CAD5 (CAD) from Cath.a-differentiated
cells, and LD9 from L929 fibroblasts [33,82]. The lines were
maintained in OBGS (Opti-MEM [Invitrogen], 4.5% Bovine
Growth Serum [Hyclone, Logan, UT], 90 units penicillin/ml,
90 mg streptomycin/ml [Invitrogen]). Cells were split 1:10, or 1:8
if sparse, twice a week. After 9 serial passages cells were replaced
with freshly thawed samples.
The Standard Scrapie Cells Assay (SSCA)
The SSCA was performed as detailed earlier [82]. In summary,
serial 1:3 dilutions of the sample (300 ml) were placed in
quadruplicate wells in 96-well plates with 5000 susceptible cells
per well. Four days after infection the confluent monolayer was
suspended and split 1:7 in OBGS for total 3 splits, allowing cells 3–
4 days to form a confluent layer between each split. After the third
split, cells were grown to confluence again, 20000 cells were added
to the wells of pre-activated Multiscreen IP96-well 0.45-mm
Immobilon P membrane plates (Millipore, Danvers, MA) and
vacuumed onto the membrane. After baking at 50uC for 1 h,
samples were treated with 1 mg proteinase K (PK, Roche)/ml in
lysis buffer, followed by PMSF and denaturation with guanidinium
thiocyanate. In more recent assays the PMSF step was omitted.
After washing with PBS, wells were blocked with 0.5% milk in 16
TBS and incubated with humanized anti-PrP antibody D18 [83]
followed by mouse anti-human IgGc AP-conjugated antibody in
0.5% milk-TBST. Signals were visualized with AP Conjugate
Substrate Kit (BioRad) and PrP
res-positive cells (‘‘spots’’) were
counted using the Bioreader 5000-Eb (BioSys). To control for
residual inoculum, the prion replication inhibitor pentosan
polysulfate (PPS) was added during the 4-day infection at 10 mg/
ml to the cells infected with the highest concentration of prion
sample.
and C57/C57/GPI
2[RML] than for C57[RML] prions, again underscoring the difference between RML prions and the novel strain. The matrix (F) also
shows that C57/GPI
2[RML] and C57/C57/GPI
2[RML] prions do not differ from each other, but that both differ significantly from C57[RML] prions. In
summary, the figure sustains the conclusion that a new strain, designated SFL, emerged after RML prions were passaged through GPI
2 brain and
returned C57 brain, and that they remained unchanged after two further passages.
doi:10.1371/journal.ppat.1002746.g003
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res-positive cells is plotted as a function of the
logarithm of the dilution. The ‘‘Response Index’’ (RI) of a sample
is the reciprocal of the concentration that gives rise to a designated
proportion of PrP
Sc-positive cells under standard assay conditions
(in our experiments, RI600, 600 positive cells per 20000 cells, or
3%).
Cell Panel Assay
The Cell Panel Assay (CPA) allows the characterization of
strains by virtue of their cell tropism and their susceptibility to
inhibitors, as determined by the SSCA performed on CAD5, PK1,
LD9 and R332H11 cells. A strain or a substrain is characterized by
the ratio of RIs on different cell lines and by the susceptibility to
Figure 4. ME7 prions propagated in tgGPI
2 mice for one or two passages acquire novel characteristics. (A) Serially diluted brain
homogenates were analyzed on LD9, CAD and PK1 cells by the CPA. After the first passage of ME7 prions in GPI
2 mice (GPI
2[ME7]), the RI on CAD
cells dropped 20-fold, most likely reflecting low titers, but increased about 30-fold after the second passage (GPI
2/GPI
2[ME7]), indicating adaptation
to the GPI
2 environment. Returning prions from the first passage in GPI
2 brain to wild-type brain (C57/GPI
2[ME7]) restored the original CPA pattern.
(B) Log[RILD9/RICAD] (red) and log[RILD9/RIPK1] (blue) are plotted as a bar graph. (C) The matrix shows that C57[ME7] and C57/GPI
2[ME7] prions do not
differ, while both differ in at least one log[ratio] from GPI
2[ME7] and GPI
2/GPI
2[ME7] prions.
doi:10.1371/journal.ppat.1002746.g004
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swainsonine (swa, Logan Natural Products; 2 mg/ml), kifunensine
(kifu, Toronto Research Chemicals Inc.; 5 mg/ml) and castanos-
permine (csp, Toronto Research Chemicals Inc.; 50 mg/ml) were
present during infection and up to the second split, and were
diluted thereafter with each split.
End-point dilution cloning of RML in cell culture
PK1 cells were seeded at 100 cells/well in 96-well plates and
inoculated with highly diluted RML-infected brain homogenates
(final concentration: 10
29;5 610
210). The cells were repeatedly
grown to confluence and subjected to three 1:3 splits, followed by
eight 1:10 splits; after a total of about 50 doublings 20000 cells
from each well were subjected to the PK-Elispot Assay and
samples containing PrP
res-positive cells (spot numbers.[back-
ground+5 SDs]) were scored as positive. The proportion of
positive wells was 27/168 (16%) for an inoculum dilution of 10
29
and 27/252 (11%) for an inoculum dilution of 5610
210;t h e
probability PN.1=1 - e
2m (1+m) that under the conditions
chosen a well was infected by more than one prion was 10
22–
10
23 or less, where m is the average number of prions/well. Nine
prion clones were expanded, conditioned media was harvested,
concentrated and inoculated into C57BL/6 mice. The brain
homogenates from terminally ill mice were characterized by the
SSCA on PK1 cells in the presence or absence of 5 mg kifu/ml for
all 9 clones from the 1
st round of cloning. In addition, prions
from several RML-infected PK1 (PK1[RML]) clones were
subjected to another round of end-point dilution cloning in cells.
Eight clones of 2
nd- round RML-infected PK1 (PK1{PK1
[RML]}) cells were expanded, conditioned media was harvested,
concentrated and inoculated into C57BL/6 mice. The brain
homogenates from three of the eight terminally-ill mice were
characterized by the SSCA on PK1 cells in the presence or
absence of 5 mg kifu/ml.
Western blot analysis
Samples were denatured by boiling in XT-MES sample buffer
(BioRad), fractionated by SDS-PAGE on 4–12% Criterion gel
(BioRad) for 1.5 h at 120 V and transferred to PVDF Immobilon
membranes (Millipore) by wet transfer (Criterion, BioRad).
Membranes were blocked in 5% non-fat dry milk/PBST and
exposed to 0.5 mg D18 anti-PrP antibody/ml in 5% non-fat dry
milk/PBST followed by mouse anti-human IgG HRP-conjugated
secondary antibody (48 ng/ml, Southern Biotech) in 5% non-fat
dry milk/PBST. Chemiluminescence was induced by ECL-Plus
(Pierce) and recorded by CCD imaging (BioSpectrum AC Imaging
System; UVP). PageRuler Plus Prestained Protein Ladder
(Fermentas) was run as molecular weight marker.
Conformational Stability Assay
The method is essentially that of Peretz et al. [23]. Prion-
infected brain homogenates (30 mg total protein) were adjusted to
between 0.5 M and 5 M guanidinium chloride (GndCl) in 10 mM
Tris-HCl (pH 8.0) (final volume 60 ml) and incubated for 15 min
at 25uC, shaking at 700 rpm in an Eppendorf thermomixer. The
GndCl concentration in each sample was then adjusted to 0.2 M
with 10 mM Tris-HCl (pH 8.0) and the volumes were equalized to
985 ml with 0.2 M GndCl in 10 mM Tris-HCl (pH 8.0). Samples
were adjusted to 0.5% Triton X-100 and digested with 0.6 mg/ml
PK (PK : protein=1:50 by weight) with shaking at 1000 rpm for
1 h at 37uC in an Eppendorf thermomixer; digestion was
terminated by addition of PMSF to 2 mM. After addition of
5 mg BSA, proteins were precipitated with TCA (10% final
concentration), chilled on ice for 30 min, and centrifuged 15 min
at 160006 g and 4uC. Pellets were resuspended in 0.5 ml cold
acetone, re-centrifuged and resuspended in 50 ml PBS-0.5%
Triton X-100. Samples were heated 10 min at 100uC in MES
sample loading buffer (Bio-RAD) and analyzed by western
blotting. Chemiluminescence was induced by ECL-Plus (Pierce),
recorded and quantified by CCD imaging (BioSpectrum AC
Imaging System; UVP). The highest value of each curve was set to
100% and the Gnd1/2 value, i.e. the GndCl concentration at
which 50% of the PrP
res was digested by PK under standard
conditions, was determined.
Sandwich ELISA
The procedure is essentially as described earlier [17]. Ninety-
six-well plates (F16 Maxisorp Nunc Immune Module, Nunc) were
rocked overnight with 15 mg/ml D18 antibody/well at 4uC,
washed with PBST 3 times, blocked with 5% milk in PBST at
37uC for 1 h, washed again in PBST 3 times and stored with
200 ml PBS per well at 4uC. Brain homogenates were diluted to
3 mg total protein/ml in 0.5% Triton X-100. Samples with high
PrP
res content were diluted appropriately with PrP
o/o brain
homogenate to give a final protein concentration of 3 mg/ml.
Samples were shaken with 12.5 mg proteinase K (PK)/ml at 37uC
for 1 h, and adjusted to 6 mM PMSF, giving a protein
concentration of 2.8 mg/ml. A 7.2-ml aliquot of each sample
was denatured with an equal volume 8 M GndCl (Research
Products International Corp.) for 5 min at 80uC and diluted in
Sandwich Assay Buffer (50 mM Tris-HCl, pH 8.0, 2% Triton X-
100, 2% sodium lauroylsarcosine, 2% BSA) to a final volume of
1 ml. Quadruplicate 300-ml sample aliquots were added to the
wells of blank 96-well tissue culture plate (BD Falcon) and serially
diluted 1:2 in Sandwich Assay Buffer. When used as a standard,
recombinant PrP (200 ng/ml in 2.8 mg/ml PrP
o/o brain homog-
enate) was serially diluted into 2.8 mg/ml PrP
o/o brain homog-
Figure 5. Conjectural free energy profile. (A) The RML quasi-species in wild-type brain are confined to a set of wells separated from those of the
SFL quasi-species by a high activation energy barrier. (B) In tgGPI
2 brain the transition to the ‘‘SFL
GPI-’’ set of conformations is enabled by a lower
activation energy barrier. (C) SFL
GPI- prions introduced into wild-type brain can now occupy, and are trapped in, the set of ‘‘SFL wells’’ which was not
accessible to RML prions in (A).
doi:10.1371/journal.ppat.1002746.g005
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coated wells and rocked 1 h at 37uC. Plates were washed 5 times
with PBST (0.1% Tween/PBS) and to each well was added 100 ml
biotinylated D13 antibody [83] at 1.3 mg/ml 1% milk-PBST. After
rocking for 1 h at 37uC in 1% milk-PBST, plates were washed 5
times with PBST and to each well was added 100 ml 1:7500 HRP-
streptavidin (Amersham GE Healthcare) in 0.5% BSA-PBST for
30 min at 37uC. After 5 washes with PBST, 100 ml TMB Super-
sensitive HRP microwell substrate (SUB2) was added, and after
2 min at room temperature the reaction was stopped with 100 ml
TMB Microwell Stop solution (STOP1; Immunochemistry
Technologies, MN). Plates were read with a BioTek 450 plate
reader (BioTek Instruments, VT) and analyzed with Gen5
software.
Supporting Information
Figure S1 Determination of kifunensine-susceptibility
of twelve independent clones of RML. PK1 cells were
infected with a high dilution of RML prions as described in the
Methods section. Prions from RML-infected clones were inocu-
lated in C57BL/6 mice and serial dilutions of homogenized brains
were analyzed by the SSCA on PK1 cells in the presence or
absence of 5 mg kifu/ml. All 12 clones were indistinguishable from
the original RML in being strongly inhibited by kifu. RML and
the clones were distinctly different from SFL, which was only
weakly inhibited by kifu. The SSCA of only one representative of
the 12 clones (#3) is shown.
(TIF)
Figure S2 Sandwich ELISA of samples from Figure 1A.
Absorbance of quadruplicate samples is plotted against input
protein on a linear plot, to show that absorbance is almost linear
with input protein up to1.5 mg/well. NBH, uninfected C57 brain
homogenate.
(TIF)
Figure S3 Conformational stability of PrP
res from
various strains. The assay was described in the Methods
section. The highest value for each curve was set to 100% and the
concentration of GndCl at which 50% of the PrP
res was digested
by PK is represented by the dotted lines. PrP
res from RML (lilac),
C57/GPI
2[RML] (green) and C57/C57/GPI
2[RML] (blue)
showed no significant differences in stabilities, which ranged from
1.7 to 1.9 M GndCl. GPI
2[RML] (red) had a marginally higher
stability (2.2 M GndCl).
(TIF)
Figure S4 Kinetic Protein Misfolding Cyclic Amplifica-
tion (PMCA). PMCA was performed to identify differences in
rate constants of amplification of PrP
res from C57[RML] and
C57/GPI
2[RML] brains. PMCA substrate (uninfected C57 brain
homogenate) was prepared as described [84], but without
centrifugation. Prion ‘‘seeds’’, RML and SFL (C57/GPI
2[RML])
PrP
res were adjusted to the same levels, as determined by
densitometric analysis on western blots. (A) PMCA reaction
mixtures contained 441 ml substrate and either 9 mlo fa1 0
22
dilution of RML or an equivalent amount of SFL PrP
res. PMCA
was performed with 60-ml aliquots of the reaction mixtures
dispensed in triplicate into 200-ml PCR tubes (Axygen) containing
3763 mg of 1.0 mm Zirconia/Silica beads (Biospec products).
Samples were subjected to cycles of 20 second sonication and
30 min incubation at 37uC for 0, 0.6, 0.9, 1.5, 2.2, 3.3 or 5 h,
using a Misonix 3000 sonicator at power setting 8.5. To measure
amplified PrP
res, 20-ml aliquots were PK-digested and 10 ml were
electrophoresed and analyzed as previously described [73]. (B)
Western blots were quantified and the ratio rPrP
res(time t)/
rPrP
res(time 0) was plotted on a log scale against time. The rate
constants were calculated from the logarithmic phases of the
kinetics (up to 3.3 h). (C) There were no statistically significant
differences (t student) in the rate constants of RML and C57/
GPI
2[RML] PrP
res amplification.
(TIF)
Table S1 Incubation periods and clinical signs for
C57BL/6 and tgGPI
2 mice inoculated with various
inocula.
(DOCX)
Text S1 Incubation periods, clinical signs, biochemical
and infectivity analyses of prion strains in tgGPI- and
wild-type C57BL/6 mice.
(DOCX)
Acknowledgments
We thank C.A.Demczyk for assistance with cell culture, M.Fallahi for
advice on statistical evaluation, M.Zhou for recombinant PrP from E.coli,
E.Smith Jr. and J.Treadaway for assistance with the SSCA, and
A.Sherman and S.Ortiz-Umpierre (SO) for carrying out the mouse
experiments.
Author Contributions
Conceived and designed the experiments: SPM CW. Performed the
experiments: SPM JJ ISK MEH AMO. Analyzed the data: JJ ISK MEH
AMO SPM CW. Contributed reagents/materials/analysis tools: MO.
Wrote the paper: SPM CW.
References
1. Endo T, Groth D, Prusiner SB, Kobata A (1989) Diversity of oligosaccharide
structures linked to asparagines of the scrapie prion protein. Biochemistry 28:
8380–8388.
2. Rudd PM, Endo T, Colominas C, Groth D, Wheeler SF, et al. (1999)
Glycosylation differences between the normal and pathogenic prion protein
isoforms. Proc Natl Acad Sci U S A 96: 13044–13049.
3. Rudd PM, Wormald MR, Wing DR, Prusiner SB, Dwek RA (2001) Prion glyco-
protein: structure, dynamics, and roles for the sugars. Biochemistry 40: 3759–3766.
4. Beringue V, Mallinson G, Kaisar M, Tayebi M, Sattar Z, et al. (2003) Regional
heterogeneity of cellular prion protein isoforms in the mouse brain. Brain 126:
2065–2073.
5. Somerville RA, Hamilton S, Fernie K (2005) Transmissible spongiform
encephalopathy strain, PrP genotype and brain region all affect the degree of
glycosylation of PrPSc. J Gen Virol 86: 241–246.
6. Monnet C, Marthiens V, Enslen H, Frobert Y, Sobel A, et al. (2003)
Heterogeneity and regulation of cellular prion protein glycoforms in neuronal
cell lines. Eur J Neurosci 18: 542–548.
7. Borchelt DR, Rogers M, Stahl N, Telling G, Prusiner SB (1993) Release of the
cellular prion protein from cultured cells after loss of its glycoinositol
phospholipid anchor. Glycobiology 3: 319–329.
8. Hegde RS, Mastrianni JA, Scott MR, DeFea KA, Tremblay P, et al. (1998) A
transmembrane form of the prion protein in neurodegenerative disease. Science
279: 827–834.
9. Hegde RS, Tremblay P, Groth D, DeArmond SJ, Prusiner SB, et al. (1999)
Transmissible and genetic prion diseases share a common pathway of
neurodegeneration. Nature 402: 822–826.
10. Goold R, Rabbanian S, Sutton L, Andre R, Arora P, et al. (2011) Rapid cell-
surface prion protein conversion revealed using a novel cell system. Nat
Commun 2: 281.
11. Campana V, Sarnataro D, Zurzolo C (2005) The highways and byways of prion
protein trafficking. Trends Cell Biol 15: 102–111.
12. Veith NM, Plattner H, Stuermer CA, Schulz-Schaeffer WJ, Burkle A (2009)
Immunolocalisation of PrPSc in scrapie-infected N2a mouse neuroblastoma cells
by light and electron microscopy. Eur J Cell Biol 88: 45–63.
RML Converted to a Novel, Stable Prion Strain
PLoS Pathogens | www.plospathogens.org 11 June 2012 | Volume 8 | Issue 6 | e100274613. Marijanovic Z, Caputo A, Campana V, Zurzolo C (2009) Identification of an
intracellular site of prion conversion. PLoS Pathog 5: e1000426.
14. Stahl N, Baldwin MA, Burlingame AL, Prusiner SB (1990) Identification of
glycoinositol phospholipid linked and truncated forms of the scrapie prion
protein. Biochemistry 29: 8879–8884.
15. Safar JG, Wille H, Itri V, Groth D, Serban H, et al. (1998) Eight prion strains
have PrP(Sc) molecules with different conformations. Nat Med 4: 1157–1165.
16. Pastrana MA, Sajnani G, Onisko B, Castilla J, Morales R, et al. (2006) Isolation
and Characterization of a Proteinase K-Sensitive PrP(Sc) Fraction. Biochemistry
45: 15710–15717.
17. Cronier S, Gros N, Tattum MH, Jackson GS, Clarke AR, et al. (2008) Detection
and characterization of proteinase K-sensitive disease-related prion protein with
thermolysin. Biochem J 416: 297–305.
18. Bruce ME, Fraser H, McBride PA, Scott JR, Dickinson AG (1992) The basis of
strain variation in scrapie. In: Prusiner SB, Collinge J, Powell J, Anderton B, eds.
Prion Diseases of Humans and Animals. New York, London: Ellis Horwood. pp
497–508.
19. Baron GS, Hughson AG, Raymond GJ, Offerdahl DK, Barton KA, et al. (2011)
Effect of glycans and the glycophosphatidylinositol anchor on strain dependent
conformations of scrapie prion protein: improved purifications and infrared
spectra. Biochemistry 50: 4479–4490.
20. Bessen RA, Marsh RF (1992) Identification of two biologically distinct strains of
transmissible mink encephalopathy in hamsters. J Gen Virol 73: 329–334.
21. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (1996) Molecular analysis of
prion strain variation and the aetiology of ‘new variant’ CJD [see comments].
Nature 383: 685–690.
22. Kuczius T, Groschup MH (1999) Differences in proteinase K resistance and
neuronal deposition of abnormal prion proteins characterize bovine spongiform
encephalopathy (BSE) and scrapie strains. Mol Med 5: 406–418.
23. Peretz D, Scott MR, Groth D, Williamson RA, Burton DR, et al. (2001) Strain-
specified relative conformational stability of the scrapie prion protein. Protein
Sci 10: 854–863.
24. Telling GC, Parchi P, DeArmond SJ, Cortelli P, Montagna P, et al. (1996)
Evidence for the conformation of the pathologic isoform of the prion protein
enciphering and propagating prion diversity. Science 274: 2079–2082.
25. Bruce ME, McBride PA, Farquhar CF (1989) Precise targeting of the pathology
of the sialoglycoprotein, PrP, and vacuolar degeneration in mouse scrapie.
Neurosci Lett 102: 1–6.
26. Fraser H, Dickinson AG (1973) Scrapie in mice. Agent-strain differences in the
distribution and intensity of grey matter vacuolation. J Comp Pathol 83: 29–40.
27. Hecker R, Taraboulos A, Scott M, Pan KM, Yang SL, et al. (1992) Replication
of distinct scrapie prion isolates is region specific in brains of transgenic mice and
hamsters. Genes Dev 6: 1213–1228.
28. Rubenstein R, Deng H, Race RE, Ju W, Scalici CL, et al. (1992) Demonstration
of scrapie strain diversity in infected PC12 cells. J Gen Virol 73: 3027–3031.
29. Nishida N, Harris DA, Vilette D, Laude H, Frobert Y, et al. (2000) Successful
transmission of three mouse-adapted scrapie strains to murine neuroblastoma
cell lines overexpressing wild-type mouse prion protein. J Virol 74: 320–325.
30. Bosque PJ, Prusiner SB (2000) Cultured cell sublines highly susceptible to prion
infection. J Virol 74: 4377–4386.
31. Vorberg I, Raines A, Story B, Priola SA (2004) Susceptibility of common
fibroblast cell lines to transmissible spongiform encephalopathy agents. J Infect
Dis 189: 431–439.
32. Lehmann S (2005) Prion propagation in cell culture. Methods Mol Biol 299:
227–234.
33. Mahal SP, Baker CA, Demczyk CA, Smith EW, Julius C, et al. (2007) Prion
strain discrimination in cell culture: the cell panel assay. Proc Natl Acad Sci U S A
104: 20908–20913.
34. Gajdusek DC (1988) Transmissible and non-transmissible amyloidoses:
Autocatalytic post-translational conversion of host precursor proteins to ß-
pleated configurations. J Neuroimmunology 20: 95–110.
35. Jarrett JT, Lansbury PJ (1993) Seeding ‘‘one-dimensional crystallization’’ of
amyloid: a pathogenic mechanism in Alzheimer’s disease and scrapie? Cell 73:
1055–1058.
36. Come JH, Fraser PE, Lansbury PJ (1993) A kinetic model for amyloid formation
in the prion diseases: importance of seeding. Proc Natl Acad Sci U S A 90:
5959–5963.
37. Weissmann C (2004) The state of the prion. Nat Rev Microbiol 2: 861–871.
38. Weissmann C (2005) Birth of a prion: spontaneous generation revisited. Cell
122: 165–168.
39. Collinge J, Clarke AR (2007) A general model of prion strains and their
pathogenicity. Science 318: 930–936.
40. Kuwata K, Kamatari YO, Akasaka K, James TL (2004) Slow conformational
dynamics in the hamster prion protein. Biochemistry 43: 4439–4446.
41. O’Sullivan DB, Jones CE, Abdelraheim SR, Brazier MW, Toms H, et al. (2009)
Dynamics of a truncated prion protein, PrP(113–231), from (15)N NMR
relaxation: order parameters calculated and slow conformational fluctuations
localized to a distinct region. Protein Sci 18: 410–423.
42. Younan ND, Klewpatinond M, Davies P, Ruban AV, Brown DR, et al. (2011)
Copper(II)-induced secondary structure changes and reduced folding stability of
the prion protein. J Mol Biol 410: 369–382.
43. Weissmann C (1991) A ‘‘unified theory’’ of prion propagation. Nature 352:
679–683.
44. Wang F, Wang X, Yuan CG, Ma J (2010) Generating a prion with bacterially
expressed recombinant prion protein. Science 327: 1132–1135.
45. Nandi PK (1998) Polymerization of human prion peptide HuPrP 106–126 to
amyloid in nucleic acid solution. Arch Virol 143: 1251–1263.
46. Gabus C, Derrington E, Leblanc P, Chnaiderman J, Dormont D, et al. (2001)
The prion protein has RNA binding and chaperoning properties characteristic
of nucleocapsid protein NCP7 of HIV-1. J Biol Chem 276: 19301–19309.
47. Gomes MP, Millen TA, Ferreira PS, e Silva NL, Vieira TC, et al. (2008) Prion
protein complexed to N2a cellular RNAs through its N-terminal domain forms
aggregates and is toxic to murine neuroblastoma cells. J Biol Chem 283:
19616–19625.
48. Nandi PK (2008) Conformational changes of prion protein and nucleic acid
arising from their interaction and relation of the altered structures in causing
prion disease. Mini Rev Med Chem 8: 784–789.
49. Deleault NR, Lucassen RW, Supattapone S (2003) RNA molecules stimulate
prion protein conversion. Nature 425: 717–720.
50. Deleault NR, Harris BT, Rees JR, Supattapone S (2007) Formation of native
prions from minimal components in vitro. Proc Natl Acad Sci U S A 104:
9741–9746.
51. Wang F, Zhang Z, Wang X, Li J, Zha L, et al. (2011) Genetic informational
RNA is not required for recombinant prion infectivity. J Virol 16: 16.
52. Kuczius T, Koch R, Keyvani K, Karch H, Grassi J, et al. (2007) Regional and
phenotype heterogeneity of cellular prion proteins in the human brain.
Eur J Neurosci 25: 2649–2655.
53. DeArmond SJ, Sanchez H, Yehiely F, Qiu Y, Ninchak-Casey A, et al. (1997)
Selective neuronal targeting in prion disease. Neuron 19: 1337–1348.
54. Telling GC, Scott M, Mastrianni J, Gabizon R, Torchia M, et al. (1995) Prion
propagation in mice expressing human and chimeric PrP transgenes implicates
the interaction of cellular PrP with another protein. Cell 83: 79–90.
55. Nishina KA, Deleault NR, Mahal SP, Baskakov I, Luhrs T, et al. (2006) The
stoichiometry of host PrPC glycoforms modulates the efficiency of PrPSc
formation in vitro. Biochemistry 45: 14129–14139.
56. Salamat MK, Dron M, Chapuis J, Langevin C, Laude H (2011) Prion
propagation in cells expressing PrP glycosylation mutants. J Virol 85:
3077–3085.
57. Cancellotti E, Bradford BM, Tuzi NL, Hickey RD, Brown D, et al. (2010)
Glycosylation of PrPC determines timing of neuroinvasion and targeting in the
brain following transmissible spongiform encephalopathy infection by a
peripheral route. J Virol 84: 3464–3475.
58. Neuendorf E, Weber A, Saalmueller A, Schatzl H, Reifenberg K, et al. (2004)
Glycosylation deficiency at either one of the two glycan attachment sites of
cellular prion protein preserves susceptibility to bovine spongiform encephalop-
athy and scrapie infections. J Biol Chem 279: 53306–53316.
59. Angers RC, Kang HE, Napier D, Browning S, Seward T, et al. (2010) Prion
strain mutation determined by prion protein conformational compatibility and
primary structure. Science 328: 1154–1158.
60. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C, et al. (2005)
Anchorless prion protein results in infectious amyloid disease without clinical
scrapie. Science 308: 1435–1439.
61. McNally KL, Ward AE, Priola SA (2009) Cells expressing anchorless prion
protein are resistant to scrapie infection. J Virol 83: 4469–4475.
62. Lee AM, Paulsson JF, Cruite J, Andaya AA, Trifilo MJ, et al. (2011) Extraneural
manifestations of prion infection in GPI-anchorless transgenic mice. Virology
411: 1–8.
63. Chesebro B, Race B, Meade-White K, Lacasse R, Race R, et al. (2010) Fatal
transmissible amyloid encephalopathy: a new type of prion disease associated
with lack of prion protein membrane anchoring. PLoS Pathog 6: e1000800.
64. Campana V, Caputo A, Sarnataro D, Paladino S, Tivodar S, et al. (2007)
Characterization of the properties and trafficking of an anchorless form of the
prion protein. J Biol Chem 282: 22747–22756.
65. Priola SA, McNally KL (2009) The role of the prion protein membrane anchor
in prion infection. Prion 3: 134–138.
66. Dickinson AG (1976) Scrapie in sheep and goats. Front Biol 44: 209–241.
67. Groschup MH, Gretzschel A, Kuczius T (2006) Prion strains. In: Hornlimann B,
Riesner D, Kretschmar H, eds. Prions in humans and animals. Berlin, New
York: de Gruyter. pp 166–183.
68. Bruce ME, McConnell I, Fraser H, Dickinson AG (1991) The disease
characteristics of different strains of scrapie in Sinc congenic mouse lines:
implications for the nature of the agent and host control of pathogenesis. J Gen
Virol 72: 595–603.
69. Nishina KA, Supattapone S (2007) Immunodetection of glycophosphatidylino-
sitol-anchored proteins following treatment with phospholipase C. Anal
Biochem 363: 318–320.
70. Tulsiani DR, Harris TM, Touster O (1982) Swainsonine inhibits the
biosynthesis of complex glycoproteins by inhibition of Golgi mannosidase II.
J Biol Chem 257: 7936–7939.
71. Tulsiani DR, Touster O (1983) Swainsonine causes the production of hybrid
glycoproteins by human skin fibroblasts and rat liver Golgi preparations. J Biol
Chem 258: 7578–7585.
72. Crispin M, Aricescu AR, Chang VT, Jones EY, Stuart DI, et al. (2007)
Disruption of alpha-mannosidase processing induces non-canonical hybrid-type
glycosylation. FEBS Lett 581: 1963–1968.
RML Converted to a Novel, Stable Prion Strain
PLoS Pathogens | www.plospathogens.org 12 June 2012 | Volume 8 | Issue 6 | e100274673. Browning S, Baker CA, Smith E, Mahal SP, Herva ME, et al. (2011) Abrogation
of complex glycosylation by swainsonine results in strain- and cell-specific
inhibition of prion replication. J Biol Chem 286: 40962–40973.
74. Li J, Browning S, Mahal SP, Oelschlegel AM, Weissmann C (2010) Darwinian
evolution of prions in cell culture. Science 327: 869–872.
75. Weissmann C, Li J, Mahal SP, Browning S (2011) Prions on the move. EMBO
Rep 12: 1109–1117.
76. Li J, Mahal SP, Demczyk CA, Weissmann C (2011) Mutability of prions. EMBO
Rep 14: 191.
77. Oelschlegel AM, Fallahi M, Ortiz-Umpierre S, Weissmann C (2012) The
Extended Cell Panel Assay (ECPA) characterizes the relationship of RML, 79A
and 139A prion strains and reveals conversion of 139A to 79A-like prions in cell
culture. J Virol 29: 29.
78. Kimberlin RH, Cole S, Walker CA (1987) Temporary and permanent
modifications to a single strain of mouse scrapie on transmission to rats and
hamsters. J Gen Virol 68: 1875–1881.
79. Bruce ME (2003) TSE strain variation. Br Med Bull 66: 99–108.
80. Legname G, Nguyen HO, Peretz D, Cohen FE, DeArmond SJ, et al. (2006)
Continuum of prion protein structures enciphers a multitude of prion isolate-
specified phenotypes. Proc Natl Acad Sci U S A 103: 19105–19110.
81. Colby DW, Prusiner SB (2011) De novo generation of prion strains. Nat Rev
Microbiol 9: 771–777.
82. Mahal SP, Browning S, Li J, Suponitsky-Kroyter I, Weissmann C (2010)
Transfer of a prion strain to different hosts leads to emergence of strain variants.
Proc Natl Acad Sci U S A 107: 22653–22658.
83. Williamson RA, Peretz D, Pinilla C, Ball H, Bastidas RB, et al. (1998) Mapping
the prion protein using recombinant antibodies. J Virol 72: 9413–9418.
84. Saa P, Castilla J, Soto C (2005) Cyclic amplification of protein misfolding and
aggregation. Methods Mol Biol 299: 53–65.
RML Converted to a Novel, Stable Prion Strain
PLoS Pathogens | www.plospathogens.org 13 June 2012 | Volume 8 | Issue 6 | e1002746